Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 331 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observational data collection Clear all

Conditions: Cardiovascular Disease, Aortic Valve Stenosis, Cognitive Assessments, Valve Surgery, Transcatheter Valve Replacement, Surgical Valve Replacement
Interventions: Observational/Cognitive Assessment; Other
Lead sponsor: Minnesota Veterans Medical Research and Education Foundation; Other
Eligibility: Up to 104 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Acute Disease, Disease Progression, Critical Illness, Biomarkers, Aging, Digital Health, Wearable Electronic Devices, Remote Patient Monitoring
Interventions: Multimodal Digital Biomarker Monitoring; Other
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2039
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: VATS-associated best practices; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Santa Monica, California • Washington D.C., District of Columbia • Austell, Georgia + 3 more

Conditions: Localized Prostate Cancer, Active Surveillance for Prostate Cancer
Interventions: Exercise, Cardiopulmonary Exercise Test (CPET); Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Arthritis
Interventions: Blood Draws for Serum Titers; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 9 Years to 26 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 4
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire; Procedure · Drug · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control; Drug · Procedure · Other
Lead sponsor: Jeffrey Gelfand; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 13 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 147
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more

Conditions: Device Performance, Healthy Adult Volunteers
Interventions: No intervention (observational study); Device
Lead sponsor: All Health, Inc.; Industry
Eligibility: 22 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Strabismus
Interventions: Provodine-Iodine Solution, Group B will receive three drops in each eye of ophthalmic balanced salt solution.; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Year to 17 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Covid19
Interventions: Observational; Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 7 more

Conditions: Sarcoma
Interventions: Surveys, Blood Collection, Saliva Collection, Urine Collection, Stool Collection, Tissue collection, Physical Activity Monitoring; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 2,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Germline BRCA Test (blood), FoundationOne Dx Genomic Profile (archival Tumour Specimen), Follow-up; Genetic · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 873 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Santa Barbara, California • Denver, Colorado • Hialeah, Florida + 10 more

Conditions: Pelizaeus-Merzbacher Disease
Interventions: Not listed
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Medical Chart Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Medical Oncology, Cancer, Healthy
Interventions: Magnetic Resonance Imaging; Other
Lead sponsor: Ezra AI, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Beverly Hills, California • Chino Hills, California • Irvine, California + 2 more

Conditions: Penile Carcinoma, Squamous Cell Carcinoma of the Penis
Interventions: Data Capture, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions: Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Critical Illness, Wounds and Injury, Disease Attributes, Pathologic Processes
Interventions: Automated Titration (O2matic); Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Aurora, Colorado • Winston-Salem, North Carolina • Portland, Oregon + 1 more

Conditions: Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 18 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more

Conditions: Hemoglobin, Cerebral Oxygenation, Congenital Heart Disease
Interventions: Noninvasive hemoglobin monitoring; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Days to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: CHD - Congenital Heart Disease, Single Ventricle Heart Disease
Interventions: vital sign monitoring; Device
Lead sponsor: Le Bonheur Children's Hospital; Other
Eligibility: 0 Months to 12 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Herpes Zoster
Interventions: Encoding of data collected in Zoster 006 and Zoster 022 studies; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 26,976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 31
States / cities: Mesa, Arizona • Phoenix, Arizona • Spring Valley, California + 26 more

Search by objective public record fields.

Evaluating the Risk of Cognitive Impairment After Surgical and Transcatheter Aortic Valve Replacement

Multimodal Digital Biomarker Prediction of Acute Clinical Deterioration

A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)

Active Surveillance Exercise Clinical Trial

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

National Cancer Institute "Cancer Moonshot Biobank"

SpO2 Validation Study - All.Health Algo Oximeter Software

The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study

Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan

International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study

Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

Collection of Outcomes Data for Pregnant Patients With Cancer

Ezra Faster Scan Study

Contemporary Characteristics of Penile Cancer

The CARDIOPROTECT Trial

Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

Observational Data Collection for Blood Hemoglobin Algorithm Validation in Pediatrics

PRecision Integrated Saturation Monitor

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022